Duchenne muscular dystrophy families are sharing stories about Elevidys complications on social media. But they aren’t ...

Shares of Sarepta Therapeutics have plunged again after the drugmaker reported a second death in connection with its gene ...

Cambridge-based Sarepta Therapeutics said it was halting shipments of its Duchenne muscular dystrophy gene therapy for ...

The death of a boy with Duchenne muscular dystrophy, tied to a gene therapy, is above all a tragedy. But it is also ...

Duchenne muscular dystrophy patient died after being treated with the gene therapy delandistrogene moxeparvovec (Elevidys), ...

在今日的市场动态中，生物技术公司Sarepta ...

Sarepta Therapeutics (NASDAQ:SRPT) reported a second fatality from acute liver failure in a patient treated with its gene ...

Another person treated with Elevidys suffered acute liver failure, leading Sarepta to discontinue treatment in certain ...

基因治疗的潜力与风险并存。Sarepta作为一家致力于开发针对DMD的创新疗法的公司，其Elevidys的研发受到了广泛关注。DMD是一种严重的遗传性肌肉疾病，患者在儿童时期便开始出现肌肉萎缩，逐渐导致失去行走能力，最终可能危及生命。基因疗法的出现，为这些患者带来了新的希望，但同时也伴随着巨大的不确定性。

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio ...

Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 44.4% in the afternoon session after the company reported a ...